Premier Path Wealth Partners, LLC Alnylam Pharmaceuticals, Inc. Transaction History
Premier Path Wealth Partners, LLC
- $777 Billion
- Q3 2025
A detailed history of Premier Path Wealth Partners, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Premier Path Wealth Partners, LLC holds 504 shares of ALNY stock, worth $226,376. This represents 0.03% of its overall portfolio holdings.
Number of Shares
504Holding current value
$226,376% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
916Shares Held
115MCall Options Held
1.26MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA16.4MShares$7.38 Billion1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.09 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.29 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.22MShares$3.24 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.04 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...